Treatment of recurrent hepatitis C following liver transplantation

Current Gastroenterology Reports

Volumn 1, Issue 1, 1999, Pages 15-19

  Bizollon, T ^a   Ducerf, C ^a   Baulieux, J ^a   Trepo, C ^a  

^a HÔTEL DIEU   (France)

Author keywords

Cholestatic Hepatitis; Follow Liver Transplantation; Liver Transplant Recipient; Liver Transplantation; Orthotopic Liver Transplantation

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REVIEW;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN;

EID: 0033068761     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-999-0081-8     Document Type: Article

References (35)

1. Kuo G, Choo QL, Alter HJ, et al.: An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989, 244:362–364.
2. Di Bisciglie AM, Goodmann ZD, Ishak KG, et al.: Long term clinical and histopathological follow up of chronic posttransfusion hepatitis. Hepatology 1991, 14:969–974.
3. Di Bisciglie AM: Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995, 15:64–69.
4. Tine F, Magin S, Craxi A, et al.: Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991, 13:192–199.
5. Ascher NL, Lake JR, Emond J, et al.: Liver transplantation for hepatitis C virus-related cirrhosis: consensus conference on indications of liver transplantation. Hepatology 1994, 20:24S-27S.
6. European Liver Transplant Registry (June 1994). Villejuif, France: Centre Hépato-Biliaire, Hopital Paul Brousse; 1994.
7. Bizollon T, Mutimer D, Ducerf C, Trepo C: Hepatitis C virus recurrence after liver transplantation. Gut 1998, in press.
8. Weiner AJ, Brauer MJ, Rosenblatt J, et al.: Variable and hypervariable domains are found in the region of HVC corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180:842–848.
9. Chazouilleres O, Kim M, Combs C, et al.: Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994, 106:994–999. This study shows the absence of relationship between posttransplantation levels of HCV RNA and the degree of histologic liver damage.
10. Ferrell L, Wright TL, Roberts J, et al.: Hepatitis C viral infection in liver transplant recipients. Hepatology 1992, 16:865–876.
11. Loinaz C, Lumbreras C, Gonzalez-Pinto I, et al.: High incidence of post-transplant hepatitis and chronic rejection associated with hepatitis C virus infection in liver transplant recipients. Transplant Proc 1995, 27:1217–1218.
12. Feray C, Gigou M, Samuel D, et al.: The course of hepatitis C virus infection after liver transplantation. Hepatology 1994, 20:1137–1143.
13. Martin P, Munoz SJ, Di Bisceglie AM, et al.: Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 1991, 13:719–721.
14. Shuhart MC, Bronner MP, Gretch DR, et al.: Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997, 26:1646–1652.
15. Casavilla A, Mateo R, Rakela J, et al.: Impact of hepatitis C virus infection on survival following primary liver transplantation under FK506 [abstract]. Hepatology 1994, 20:133A.
16. Gane EJ, Portmann BC, Naoumov NV, et al.: Long term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815–820. This study including 149 patients with HCV infection investigated the natural history of HCV infection in liver-transplant patients. After 5 years, the rates of graft loss and overall survivals are similar between patients and those without HCV infection.
17. Singh N, Gayowsky T, Wagener MM, et al.: Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996, 61:402–406.
18. Boker KHW, Dalley G, Bahr MJ, et al.: Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997, 25:203–210.
19. Lim HL, Lau GKK, Davis GL, et al.: Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatiti C virus infection. Gastroenterology 1994, 106:248–251.
20. Schluger LK, Sheiner PA, Thung SN, et al.: Severe recurren cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996, 23:971–976.
21. Wright HI, Gavaler JS, Van Thiel DH: Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992, 53:121–124.
22. Wright TL, Combs C, Kim M, et al.: Interferon alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994, 20:773–779.
23. Feray C, Samuel D, Gigou M, et al.: An open trial of IFN alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995, 22:1084–1089.
24. Cattral MS, Krajden M, Wanless IR, et al.: A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996, 61:1483–1488.
25. Gane EJ, Tibbs CJ, Ramage JK, et al.: Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant Int 1995, 8:61–64.
26. Bizollon T, Palazzo U, Ducerf C, et al.: Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997, 26:500–504. This pilot study shows the efficacy and the good tolerance of immunoreactive fibronectin interferon plus ribavirin in the treatment of HCV recurrence following liver transplantation.
27. Heagy W, Crumpacker C, Lopez PA, et al.: Inhibition of immune functions by antiviral drugs. J Clin Invest 1991, 87:1916–1924.
28. Jolley W, Sharma B, Chami R, et al.: Long-term skin allograft survival by combined therapy with suboptimal dose of cyclosporin and ribavirin. Transplant Proc 1988, 20:703–706.
29. Sheiner PA, Schluger LK, Emre S, et al.: Retransplantation for recurrent hepatitis C. Liver Tranplant Sur 1997, 3:130–136. This study reports for the first time the outcome of 14 patients retransplanted for recurrent hepatitis. Retransplantation for hepatitis C should be considered a viable option for patients who develop endstage hepatic dysfunction secondary to HCV recurrent diseas.
30. Van Thiel DH, Faruki H, Fagioli H, et al.: Successful treatment of end-stage liver disease due to hepatitis C prio to liver transplantation [abstract]. Hepatology 1994, 20:137A.
31. Singh N, Gayowski T, Wannstedt CF, et al.: Interferon-a for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Tranpslantation 1998, 65:82–86. In this randomized study, for only 6 months immunoreactive fibronectin interferon delayed the occurrence of HCV hepatitis on the graft, but did not decrease the incidence nor the severity of HCV hepatitis after orthotopic liver transplantation.
32. Sheiner PA, Boros P, Klion FM, et al.: The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998, 28:831–838. This randomized study shows for the first time the efficacy of prophylactic immunoreactive fibronectin interferon monotherapy in the prevention of hepatitis on the graft. In this protocol the drug was initiated 2 weeks after orthotopic liver transplantation for a duration of 12 months.
33. Bizollon T, Chevallier P, Adahm M, et al.: IgM anti-hepatitis virus core antibodies correlate with hepatitis C recurrence and his severity in liver transplant patients. J Hepatol, in press.
34. Krawczynski K, Alter MJ, Tankersley DL, et al.: Studies on protective efficacy of hepatitis C immunoglobulins in experimental hepatitis C infection [abstract]. Hepatology 1993, 17:110A.
35. Feray C, Samuel D, Gigou M, et al.: Reduced incidence of recurrent and acquired infection by HCV after liver transplantation in patients receiving immunoglobulins [abstract]. Hepatology 1994, 20:131A.